Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-768-6 | CAS number: 5064-31-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June 1997 - August 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
- Objective of study:
- absorption
- excretion
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.36 (Toxicokinetics)
- Version / remarks:
- EC Commission Directive 87/302/EEC of November 18, 1987; Part B: Methods for the determination of Toxicity, Toxicokinetics; Official Journal of the European Communities No. L 133, p. 51-54, 1988
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Trisodium nitrilotriacetate
- EC Number:
- 225-768-6
- EC Name:
- Trisodium nitrilotriacetate
- Cas Number:
- 5064-31-3
- Molecular formula:
- C6H9NO6.3Na
- IUPAC Name:
- trisodium 2-[bis(carboxylatomethyl)amino]acetate
- Details on test material:
- - Name of test material (as cited in study report): Trilon A 92 (Tri-sodium salt of nitrilo tri (acetic) acid, monohydrate)
- Substance type: pure substance
- Physical state: solid, white powder
- Analytical purity: 92.4 %
- Impurities (identity and concentrations): no data
- Purity test date: IR- and UV-spectroscopy- analysis of Oct. 95, confirmation in Oct. 1997
- Lot/batch No.: Abl. Nr. 05-5056
- Expiration date of the lot/batch: no data
- Stability under test conditions: stability was checked in all experiments
- Storage condition of test material: at ambient temperature, tightly closed
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Karl Thomae, Biberach a.d. Riss (Germany)
- Age at study initiation: 8 weeks at the beginning of acclimatization
- Weight at study initiation: between 281 and 308 g
- Fasting period before study: no data
- Housing: During acclimatization and prior to the experiment in type III Macrolon cages. During balance experiments in all-glass metabolism cages; type Metabowl (Jencons, Leighton Buzzard, UK)
- Individual metabolism cages: yes
- Diet (e.g. ad libitum): ad libitum. Kliba lab diet for rat-mouse-hamster either pelleted (e.g. during acclimatization) or granulated (e.g. in metabolism cages). Origin: Klingentalmühle AG, CH-4303 Kaiseraugst, Switzerland
- Water (e.g. ad libitum): Tap water ad libitum
- Acclimation period: period unspecified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24 °C
- Humidity (%): 30 - 70 %
- Air changes (per hr): air conditioned
- Photoperiod (hrs dark / hrs light): no data
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Trilon A 92 was dissolved in the respective amount of a solution of 0.5 % Tylose CB 30.000 in aqua bidest .
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): no data
- Mixing appropriate amounts with (Type of food): Trilon A 92 in 0.5 % Tylose CB 30.000 in aqua bidest
- Storage temperature of food: at ambient temperature
VEHICLE
- Justification for use and choice of vehicle (if other than water): Recognized by international guidelines as the recommended test system (OECD No. 417). Study results will be used in. relation to already available data from the same test system.
- Concentration in vehicle:
- Amount of vehicle (if gavage): About 1 ml of the Tylose solution / 100 g bw were administered by gavage
HOMOGENEITY AND STABILITY OF TEST MATERIAL:
The analytical investigations performed in the context of this study demonstrated the stability of Trilon A 92 in 0.5 % Tylose CB 30.000 in aqua bidest . and the correctness of the concentrations. - Duration and frequency of treatment / exposure:
- single dose (low and high) and
repeated dose (high): once daily at about the same time for 7 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Single oral administration:
high dose 500 mg/kg bw
low dose 25 mg/kg bw
Repeated oral administration:
high dose 500 mg/kg bw
- No. of animals per sex per dose / concentration:
- 4 males for each Experiment (dose)
- Control animals:
- no
- Details on study design:
- - Dose selection rationale:
According to the relevant guidelines (OECD No. 417), experiments shall be performed using one "high" dose level which should cause slight toxic effects and at which there might be changes in toxicokinetic parameters and one "low" dose level causing no toxic effects. The above mentioned doses of 500 and 25 mg/kg bw have been selected using the results from previously performed studies on the biokinetics and subacute or subchronic toxicity with Trilon A 92 (ref. 1-3).
As the study results should be set in relation to already available data from the same test system, the same mode of administration (oral) was used. - Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled (delete / add / specify): urine, cage washes
- Time and frequency of sampling:
For single oral administration experiments: urine collection in time intervals: 0-6 h, 6-12 h, 12-24 h, 24-48 h, and 48-72 h
For repeated oral administration experiments: Collection of urine in 24 h intervals and 6, 12, 24 48 and 72 h after the last administration - Statistics:
- Analysis of kinetic data was performed based on the group mean values using the PC program system TOPFIT Version 2.0
Calculation of group mean value and standard deviation
Results and discussion
- Preliminary studies:
- Based on theoretical considerations and published data, it was assumed that the systemically available portion of dose, i.e. the absorbed portion of dose, is exclusively excreted via urine and no metabolism of Trilon A 92 occurs. The portion of dose of Trilon A 92 which is found
in urine, thus, directly gives the bioavailability of Trilon A 92. For this reason only urine samples were analyzed for Trilon A 92.
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- rapid but incomplete (~50% after 72h)
- Type:
- excretion
- Results:
- rapid for single and repeated dosing with an urinary excretion half-life of about 5 to 6 h
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Single oral administration of high dose:
(nominally 500 mg/kg bw (actually received on average: 440.9 mg/kg bw) corresponding to 132.05 mg per animal.)
Within 72 hours after single oral administration to male rats 40.71 % of the applied dose was found in urine. => bioavailability 40.71 %
Single oral administration of low dose:
(nominally 25 mg/kg bw (actually received on average: 21.8 mg/kg bw) corresponding to 6.6 mg per animal.)
Within 72 hours after single oral administration to male rats 53.03 % of the applied dose was found in urine. => bioavailability 53.03 %
Repeated oral administration of high dose:
(nominally 500 mg/kg bw /day (actually received on average: 453.4 mg/kg bw/day) resulting in a mean total dose of 878.91 mg per animal over 7 days of treatment.)
Continuously decreasing body weight during treatment period.
Increasing body weight during 72 hour observation period after last administration.
47.81 % of the total dose applied could be found in the urine collected during the treatment period and up to 72 hours after the last administration. => bioavailability over 7 days = 47,81 % (with some variations on a daily basis: range: 27.89 % on day 3 and 62.09 on day 4)
- Details on excretion:
- Single oral administration of high dose:
The urinary excretion half-life of Trilon A 92 was calculated to be 6.2 hours.
Kinetic analysis revealed a mean residence time of Trilon A 92 of 11.9 hours.
Single oral administration of low dose:
The urinary excretion half-life of Trilon A 92 was calculated to be 4.7 hours.
Kinetic analysis revealed a mean residence time of Trilon A 92 of 6.5 hours.
Repeated oral administration of high dose:
The urinary excretion half-life of Trilon A 92 was calculated to be 5.4 hours.
Kinetic analysis revealed a mean residence time of Trilon A 92 of 8.5 hours.
All these data do not give an indication that induction or saturation of urinary excretion of Trilon A 92 occurs after repeated oral administration.
Toxicokinetic parametersopen allclose all
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: 6.2 hours (high dose single administration)
- Test no.:
- #2
- Toxicokinetic parameters:
- half-life 1st: 4.7 hours (low dose single administration)
- Test no.:
- #3
- Toxicokinetic parameters:
- half-life 1st: 5.4 hours (high dose repeated administration)
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
Table 1: Excretion of Trilon A 92 after single oral administration to male rats at a dose level of 500 mg/kg bw (mena values and standard deviation)
.
Animal No. |
mean |
SD |
Animal weight in [g] |
|
|
at application |
299,48 |
11,93 |
at sacrifice |
284,47 |
16,50 |
Dose In [mg/kg bw] |
440,90 |
6,60 |
Dose in [mg/animal] |
132,05 |
6,31 |
|
|
|
Urinary excretion in |
% dose (mean) |
SD |
Urine 0-6 |
19,72 |
4,84 |
Urine 6-12 |
10,08 |
2,78 |
Urine 12-24 |
7,28 |
1,98 |
Urine 24-48 |
2,00 |
0,88 |
Urine 48-72 |
1,65 |
1,20 |
Cage wash |
0,00 |
0,00 |
|
|
|
Total |
40,71 |
4,50 |
Table 2: Excretion of Trilon A 92 after single oral administration to male rats at a dose level of 25 mg/kg bw (mean values and standard deviation)
Animal No. | mean | SD |
Animal weight in [g] | ||
at application | 306,12 | 7,60 |
at sacrifice | 292,27 | 5,54 |
Dose In [mg/kg bw] | 21,80 | 0,20 |
Dose in [mg/animal] | 6,66 | 0,18 |
Urinary excretion in | % dose (mean) | SD |
Urine 0-6 | 32,16 | 6,64 |
Urine 6-12 | 14,04 | 4,76 |
Urine 12-24 | 6,83 | 4,90 |
Urine 24-48 | 0,00 | 0,00 |
Urine 48-72 | 0,00 | 0,00 |
Cage wash | 0,00 | 0,00 |
Total | 53,03 | 13,94 |
Table 3: Excretion of Trilon A 92 after daily oral administration for 7 consecutive days to male rats at a dose level of 500 mg/kg bw (mean values and standard deviation)
Animal weight in [g] | Dosing in [mg/kg bw] | Dosing in [mg/animal] | Urinary excretion in [% of daily dose] | |||||
mean | SD | mean | SD | mean | SD | mean | SD | |
Day 1 | 305,86 | 2,11 | 446,2 | 4,80 | 136,48 | 1,71 | 61,39 | 5,43 |
Day 2 | 280,38 | 4,09 | 443,1 | 7,00 | 124,2 | 0,55 | 52,37 | 5,89 |
Day 3 | 278,70 | 5,12 | 448,8 | 6,50 | 125,08 | 3,36 | 27,89 | 6,85 |
Day 4 | 274,64 | 3,76 | 454,1 | 12,70 | 124,75 | 5,02 | 62,09 | 13,14 |
Day 5 | 268,00 | 5,99 | 461,1 | 19,20 | 123,65 | 7,76 | 43,87 | 2,91 |
Day 6 | 270,75 | 5,12 | 459,6 | 1,30 | 124,42 | 2,48 | 42,87 | 11,33 |
Day 7 | 261,21 | 6,39 | 460,8 | 11,80 | 120,33 | 3,15 | 42,81 | 6,64 |
At sacrifice | 296,46 | 8,90 | ||||||
Mean | 453,4 | 3,90 | ||||||
Total | 878,91 | 16,68 |
Table 4: Excretion of Trilon A 92 after daily oral administration for 7 consecutive days to male rats at a dose level of 500 mg/kg bw (mean values % dose and standard deviation)
Urinary excretion of test substance | % dose (mean) | SD |
Urine 0-24 | 9,54 | 0,95 |
Urine 24-48 | 7,4 | 0,75 |
Urine 48-72 | 3,97 | 0,96 |
Urine 72-96 | 8,8 | 1,84 |
Urine 96-120 | 6,18 | 0,65 |
Urine 120-144 | 6,07 | 1,61 |
Urine 144-150 | 3,57 | 0,63 |
Urine 150-156 | 1,29 | 0,34 |
Urine 156-168 | 0,69 | 0,15 |
Urine 168-192 | 0,19 | 0,13 |
Urine 192-216 | 0,11 | 0,11 |
Cage wash | 0 | 0,00 |
Total | 47,81 | 4,19 |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
After single and repeated oral administration Na3NTA was rapidly absorbed from the gastrointestinal tract. Absorption, however, was incomplete amounting to about 50 % of the dose applied. The excretion of Na3NTA was rapid with an urinary excretion half-life of about 5-6 hours. - Executive summary:
In an absorption and excretion study according to OECD 417 Na3NTA was administered to male Wistar rats in single oral administration at dose levels of 500 mg/kg and 25 mg/kg bw, and repeated oral administration at a dose level of 500 mg/kg/day, nominally.
After single and repeated oral administration Na3NTA was rapidly absorbed from the gastrointestinal tract. Absorption, however, was incomplete amounting to about 50 % of the dose applied. Excretion was rapid with an urinary excretion half-life of about 5-6 hours.
The investigation does not give an indication that induction or saturation of urinary excretion of Na3NTA occurs after repeated oral administration. The experiment does not indicate any bioaccumulation potential.
This absorption and excretion study in male Wistar rats is classified acceptable and satisfies the guideline requirements in rats according to OECD 417.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.